The i.v. transplantation model accurately recapitulated ASC sensitivity to the clinically relevant pan-ERBB inhibitor afatinib, through both short-term ablation of localized tumor progression and extended survival upon longer treatment (Moll et al., 2018; Talwelkar et al., 2019). The gene discussed is EGFR; the disease is neoplasm.